Skip to main content
In stock | Targeted Therapy (Antibody)

Naxitamab

Oncology Type Solid Tumour (Sarcoma/Neuroblastoma)
Drug Class / Mechanism PDGFR / GD2 Targeting Agent
No Image
Description

Naxitamab is classified as a PDGFR / GD2 Targeting Agent, sourced for use within our Targeted Therapy (Antibody) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy (Antibody)
Oncology Type Solid Tumour (Sarcoma/Neuroblastoma)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3